Longboard Pharmaceuticals, Inc.
LBPH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LBPH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Sep 30, 2024.
Tracking 4 clinical trials for Longboard Pharmaceuticals, Inc..
Run Longboard Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Longboard Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
40.3 months
D/E 0.08 · 13% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Governance
Frequently asked questions
Who is the CEO of Longboard Pharmaceuticals, Inc.?
Chief Executive Officer is the chief executive officer of Longboard Pharmaceuticals, Inc. (LBPH).
What therapeutic areas does Longboard Pharmaceuticals, Inc. focus on?
Longboard Pharmaceuticals, Inc. develops therapies across Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.